Astellas Pharma Inc. is a Japanese pharmaceutical company with a global presence. It has been engaged in the business of pharmaceutical products since 2004 and has established itself as a trusted name ...

That was followed shortly after by the FDA approval of Astellas' C5 inhibitor Izervay ... Longitude Capital, OrbiMed, Logos Capital, Marshall Wace, Catalio Capital Management, funds managed ...

Astellas Pharma (ALPMY) and Pfizer (PFE) announced longer-term follow-up results from an open-label extension of the Phase 3 ...

Astellas Pharma Inc. (ALPMY) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company ...

Astellas Pharma Inc. (ALPMY) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in ...

Thank you very much for joining our FY 2024 Financial Results Announcement Meeting by Astellas Pharma Inc. out of your very busy schedule today. I'm delighted to serve as a moderator. I'm Ikeda ...

The global pharmaceutical industry is grappling with an uncertain outlook, amid President Donald Trump's plans to cut US ...

TOKYO, May 19, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") will present 16 abstracts featuring new data across its approved cancer therapies ...